www.aspenpharma.com
Open in
urlscan Pro
151.101.66.159
Public Scan
Submitted URL: http://www.aspenpharma.com/
Effective URL: https://www.aspenpharma.com/
Submission: On February 24 via manual from US — Scanned from DE
Effective URL: https://www.aspenpharma.com/
Submission: On February 24 via manual from US — Scanned from DE
Form analysis 1 forms found in the DOM
GET https://www.aspenpharma.com/
<form aria-label="Search" method="get" role="search" action="https://www.aspenpharma.com/" title="Type and press Enter to search.">
<input aria-label="Search" type="search" class="fl-search-input form-control" name="s" placeholder="Search" value="" onfocus="if (this.value === 'Search') { this.value = ''; }" onblur="if (this.value === '') this.value='Search';">
</form>Text Content
logo
* Consent
* Details
* [#IABV2SETTINGS#]
* About
THIS WEBSITE USES COOKIES
We use cookies to personalise content and ads, to provide social media features
and to analyse our traffic. We also share information about your use of our site
with our social media, advertising and analytics partners who may combine it
with other information that you’ve provided to them or that they’ve collected
from your use of their services.
Consent Selection
Necessary
Preferences
Statistics
Marketing
Show details
Necessary 2
Necessary cookies help make a website usable by enabling basic functions like
page navigation and access to secure areas of the website. The website cannot
function properly without these cookies.
Cookiebot
1
Learn more about this provider
CookieConsentStores the user's cookie consent state for the current domain
Expiry: 1 yearType: HTTP
www.aspenpharma.com
1
PHPSESSIDPreserves user session state across page requests.
Expiry: SessionType: HTTP
Preferences 2
Preference cookies enable a website to remember information that changes the way
the website behaves or looks, like your preferred language or the region that
you are in.
Vimeo
2
Learn more about this provider
playerSaves the user's preferences when playing embedded videos from Vimeo.
Expiry: 1 yearType: HTTP
sync_activeContains data on visitor's video-content preferences - This allows
the website to remember parameters such as preferred volume or video quality.
The service is provided by Vimeo.com.
Expiry: PersistentType: HTML
Statistics 6
Statistic cookies help website owners to understand how visitors interact with
websites by collecting and reporting information anonymously.
Issuu
2
Learn more about this provider
sessionPageNumbersSets a unique ID for the session. This allows the website to
obtain data on visitor behaviour for statistical purposes.
Expiry: SessionType: HTML
sessionStartTimeDetermines when the visitor last visited the different subpages
on the website, as well as sets a timestamp for when the session started.
Expiry: SessionType: HTML
Vimeo
1
Learn more about this provider
vuidCollects data on the user's visits to the website, such as which pages have
been read.
Expiry: 2 yearsType: HTTP
www.aspenpharma.com
3
_gaRegisters a unique ID that is used to generate statistical data on how the
visitor uses the website.
Expiry: 2 yearsType: HTTP
_gatUsed by Google Analytics to throttle request rate
Expiry: 1 dayType: HTTP
_gidRegisters a unique ID that is used to generate statistical data on how the
visitor uses the website.
Expiry: 1 dayType: HTTP
Marketing 1
Marketing cookies are used to track visitors across websites. The intention is
to display ads that are relevant and engaging for the individual user and
thereby more valuable for publishers and third party advertisers.
Issuu
1
Learn more about this provider
iutkRecognises the user's device and what Issuu documents have been read.
Expiry: 179 daysType: HTTP
Unclassified 0
Unclassified cookies are cookies that we are in the process of classifying,
together with the providers of individual cookies.
We do not use cookies of this type.
Cross-domain consent[#BULK_CONSENT_DOMAINS_COUNT#] [#BULK_CONSENT_TITLE#]
List of domains your consent applies to: [#BULK_CONSENT_DOMAINS#]
Cookie declaration last updated on 29.01.22 by Cookiebot
[#IABV2_TITLE#]
[#IABV2_BODY_INTRO#]
[#IABV2_BODY_LEGITIMATE_INTEREST_INTRO#]
[#IABV2_BODY_PREFERENCE_INTRO#]
[#IABV2_LABEL_PURPOSES#]
[#IABV2_BODY_PURPOSES_INTRO#]
[#IABV2_BODY_PURPOSES#]
[#IABV2_LABEL_FEATURES#]
[#IABV2_BODY_FEATURES_INTRO#]
[#IABV2_BODY_FEATURES#]
[#IABV2_LABEL_PARTNERS#]
[#IABV2_BODY_PARTNERS_INTRO#]
[#IABV2_BODY_PARTNERS#]
Cookies are small text files that can be used by websites to make a user's
experience more efficient.
The law states that we can store cookies on your device if they are strictly
necessary for the operation of this site. For all other types of cookies we need
your permission.
This site uses different types of cookies. Some cookies are placed by third
party services that appear on our pages.
You can at any time change or withdraw your consent from the Cookie Declaration
on our website.
Learn more about who we are, how you can contact us and how we process personal
data in our Privacy Policy.
Please state your consent ID and date when you contact us regarding your
consent.
[#OOI_PERSONAL_INFORMATION#]
Deny Allow selection Customize
OK
Powered by Cookiebot by Usercentrics
2021 Year End Results
Presentation
Skip to content
Group Sites
* Africa Middle East
* Ghana-Kama
* Kenya-Beta Healthcare
* Mauritius
* MENAT
* Nigeria
* South Africa-Ethicare
* South Africa-FCC
* South Africa-HOLDINGS
* South Africa-Nutritionals
* South Africa-Pharmacare
* Tanzania-Shelys
* Americas
* Brazil
* Canada
* Mexico
* USA
* Asia
* China
* Japan
* Malaysia
* Philippines
* Taiwan
* Australasia
* Australia
* New Zealand
* Europe CIS
* Austria
* Czech Republic
* France
* France-NDB
* Germany
* Netherlands
* Netherlands OSS
* Netherlands-Aspen API
* Russia
* Slovakia
* SPAIN
* SWITZERLAND
* Ghana-Kama
* Kenya-Beta Healthcare
* Mauritius
* MENAT
* Nigeria
* South Africa-Ethicare
* South Africa-FCC
* South Africa-HOLDINGS
* South Africa-Nutritionals
* South Africa-Pharmacare
* Tanzania-Shelys
* Brazil
* Canada
* Mexico
* USA
* China
* Japan
* Malaysia
* Philippines
* Taiwan
* Australia
* New Zealand
* Austria
* Czech Republic
* France
* France-NDB
* Germany
* Netherlands
* Netherlands OSS
* Netherlands-Aspen API
* Russia
* Slovakia
* SPAIN
* SWITZERLAND
OUR RESPONSE TO COVID-19
Menu
*
* About
Aspen
* * Group overview
* Global presence
* Board of Directors
* * Group Executive Committee
* History
* Corporate governance and risk management
* * Ethics & Compliance Management
* Our response to COVID-19
* Close
* Business
Segments
* * Regional Overviews
* Africa Middle East
* Americas
* Asia
* Australasia
* Europe CIS
* * * Sterile Focus Brands
* Regional Brands
* Manufacturing
* * Manufacturing Capabilities
* Close
* Investor
Relations
* * Investor overview
* SENS
* Share price centre
* * Shareholder centre
* Investor Information
* Supplementary documents
* * Investor calendar
* Close
* We
Care
* * We Care Initiatives
* We Care Videos
* * Mandela Day
* Responsible Corporate Citizenship
* * Healthcare Heroes
* Diversity & Inclusion
* Close
* Sustainability
* * Sustainability overview
* * Supplementary sustainability documents
*
* Close
* Group News
* * Group news
* * Media coverage
*
* Close
* Careers
* * Working for Aspen
* * Aspen jobs
*
* Close
* Contact Us
* * Contact form
* * Contact details
* * Global contact details
* Close
Menu
*
* About
Aspen
* * Group overview
* Global presence
* Board of Directors
* * Group Executive Committee
* History
* Corporate governance and risk management
* * Ethics & Compliance Management
* Our response to COVID-19
* Close
* Business
Segments
* * Regional Overviews
* Africa Middle East
* Americas
* Asia
* Australasia
* Europe CIS
* * * Sterile Focus Brands
* Regional Brands
* Manufacturing
* * Manufacturing Capabilities
* Close
* Investor
Relations
* * Investor overview
* SENS
* Share price centre
* * Shareholder centre
* Investor Information
* Supplementary documents
* * Investor calendar
* Close
* We
Care
* * We Care Initiatives
* We Care Videos
* * Mandela Day
* Responsible Corporate Citizenship
* * Healthcare Heroes
* Diversity & Inclusion
* Close
* Sustainability
* * Sustainability overview
* * Supplementary sustainability documents
*
* Close
* Group News
* * Group news
* * Media coverage
*
* Close
* Careers
* * Working for Aspen
* * Aspen jobs
*
* Close
* Contact Us
* * Contact form
* * Contact details
* * Global contact details
* Close
Integrated Report 2021
Click to view online
Click to download
Annual Financial Statements 2021
Click to download
Integrated Report 2021
Click to view online
Click to download
Annual Financial Statements 2021
Click to download
2021 Integrated
Report
2021 Annual Financial
Statements
ABOUT ASPEN
Headquartered in Durban, South Africa, we are a global specialty and branded
pharmaceutical company, improving the health of patients across the world
through our high quality and affordable medicines. Active at every stage of the
value chain, we are uniquely diversified by geography, product and manufacturing
capability.
With an acknowledged presence of more than two decades in the pharmaceutical
sector, we improve the health of patients in more than 150 countries. The
Group’s key business segments are Manufacturing and Commercial Pharmaceuticals
comprising Regional Brands and Sterile Focus Brands.
Group Overview
REGISTER FOR ALERTS
Register via Vault for alerts of SENS announcements, reports and event
invitations.
BOARD OF DIRECTORS
--------------------------------------------------------------------------------
INVESTOR OVERVIEW
--------------------------------------------------------------------------------
INVESTOR INFORMATION
--------------------------------------------------------------------------------
SUSTAINABILITY DOCUMENTS
GROUP NEWS
ASPEN PRESENTED WITH 2022 ECONOMIC DIPLOMACY (GLOBAL) UBUNTU AWARD
12 Feb 2022
Read More
ASPEN CONFIRMS NON-BINDING TERM SHEET ON MANUFACTURE AND SALE OF AN ASPEN-
BRANDED COVID-19 VACCINE THROUGHOUT AFRICA
30 Nov 2021
Read More
ASPEN WELCOMES KENYAN PRESIDENT UHURU KENYATTA TO ITS GQEBERHA MANUFACTURING
SITE
24 Nov 2021
Read More
More Group News
SENS ANNOUNCEMENTS
MORE SENS
INVESTOR CALENDAR
09
March 2022 Interim results SENS announcement
10
March 2022 Interim results presentation: Cape Town, Mount Nelson Hotel
15
March 2022 JP Morgan South African Healthcare Seminar (virtual)
29
March 2022 Bank of America Securities 23rd Annual Sun City Conference (virtual)
31
August 2022 Annual results SENS announcement
01
September 2022 Annual results presentation
12
September 2022 13th Annual RMB Morgan Stanley Big Five Investor Conference
08
December 2022 Annual General Meeting
LATEST RESULTS
2021 Integrated reporting
Aspen 2021 Integrated reporting
* View online
* PDF 30 MB
Aspen 2021 Annual Financial Statements
* PDF 1.2 MB
Aspen 2021 Corporate Brochure
* PDF 284 KB
Year End results - 30 June 2021
Aspen Year End Results Presentation
* PDF 9.7Mb
Aspen reviewed provisional financial results for the year ended 30 June 2021
* PDF 147KB
Aspen year end results short form announcement
* PDF 67KB
Aspen year end results webcast recording
* Webcast
More results
More Group News
MORE SENS
Read more
More results
REGIONAL
OVERVIEWS
AFRICA MIDDLE EAST
AMERICAS
ASIA
AUSTRALASIA
EUROPE CIS
AFRICA MIDDLE EAST
AMERICAS
ASIA
AUSTRALASIA
EUROPE CIS
AFRICA MIDDLE EAST
AMERICAS
ASIA
AUSTRALASIA
EUROPE CIS
AFRICA MIDDLE EAST
AMERICAS
ASIA
AUSTRALASIA
EUROPE CIS
AFRICA MIDDLE EAST
AMERICAS
ASIA
AUSTRALASIA
EUROPE CIS
AFRICA MIDDLE EAST
This region represents the single largest revenue contributor in the Commercial
Pharmaceuticals segment, with revenues predominantly from Regional Brands. Aspen
supplies well-established local brands, as well as internationally recognised
medicines across multiple countries in the region, supported by commercial and
sales employees. Extensive and differentiated manufacturing capabilities
including high potency and hormonal solids, vaccines and other state-of-the-art
sterile capabilities exist at one of the Group’s primary manufacturing sites in
Gqeberha, South Africa. This primary site is complemented by five regional sites
across the continent.
Key countries
Egypt
Kenya
Kingdom of Saudi Arabia
South Africa
Tanzania
Number of products launched:
48
(2020: 29)
STATISTICS
The South African private pharmaceutical sector was valued at R49,8 billion MAT*
for the period ended July 2021.
In South Africa, four out of the top 15 brands in the private sector were Aspen
products.
Source: IQVIA, IQVIA Midas 2021 and Market Prognosis Global. South Africa and
Middle East and North Africa only.
Sub-Saharan Africa (“SSA”) not covered by IQVIA
*MAT = Moving annual total
AMERICAS
Aspen’s presence in the Americas is dominated by the businesses in Latin
America. Mexico and Brazil are the largest contributors to regional performance.
Aspen provides a range of trusted brands across prescription, hospital and
over-the-counter medicines and operates one finished dose form manufacturing
facility in Brazil.
Key countries
Brazil
Canada
Chile
Colombia
Ecuador
Mexico
USA
Number of products launched:
3
(2020: 8)
STATISTICS
The Mexican pharmaceutical market grew 14,0% to USD10,8 billion MAT* June 2021,
positively impacted by double-digit growth across the generic and ethical
markets.
Pharmaceutical sales across the total Spanish Latin America market grew 20% to
USD21,3 billion MAT June 2021.
Source: IQVIA – June 2021
*MAT = Moving annual total
ASIA
This region comprises all Asian territories where we sell products, including
China. Active trading subsidiaries include those in China, the Philippines,
Taiwan and Malaysia with other countries in the region reached via distributors.
Sterile Focus Brands are the key contributor to revenue. Our manufacturing
facility in India is our primary new product development site.
Key countries
China
Malaysia
Philippines
Singapore
Taiwan
Number of products launched:
3
(2020: 1)
STATISTICS
The Chinese general anaesthesia therapy area consists of inhalation and
intravenous products. The propofol market grew 10,6% year-on-year MAT* May 2021.
The South Korean pharmaceutical market is forecast to grow at a CAGR of 6%
between 2019 and 2024, reaching Won24,579 billion by 2024.
Source: China IMS CHPA Report, May 2021.
*MAT = Moving annual total
Source: China IMS CHPA Report, May 2021.
*MAT = Moving annual total
AUSTRALASIA
One of the largest pharmaceutical companies in the Australasia region, with a
comprehensive portfolio of medicines comprising Regional Brands, including
prescription and over-the-counter products, as well as Sterile Focus Brands. A
widely-accredited manufacturing facility is operated in Australia, producing
finished dose form solids, liquids and semi-solids as well as packaging for
third party contract manufacturing for domestic and export markets.
Key countries
Australia
New Zealand
Number of products launched:
2
(2020: 2)
STATISTICS
The Australian and New Zealand pharmaceutical market combined, grew 1,9% and was
valued at AUD20,7 billion MAT* to May 2021.
Source: IQVIA – August 2020
*MAT = Moving annual total
EUROPE CIS
Europe CIS provides a broad range of Sterile Focus and Regional Brands while
operating a range of manufacturing facilities for Aspen’s own production needs,
as well as manufacturing for third parties. Sterile Focus Brands comprise
anaesthetics and thrombosis in Russia and the other CIS countries only.
Manufacturing activities include active pharmaceutical ingredients and finished
dose form production and our sites are widely accredited. The prefilled syringe
and multi-dose form sites in France and Germany respectively, provide finished
dose form medicines for commercialisation by Aspen and third parties for both
domestic and export markets.
Key countries
France
Germany
Netherlands
Russian Federation
United Kingdom
Number of products launched:
1
(2020: Nil)
STATISTICS
AFRICA MIDDLE EAST
This region represents the single largest revenue contributor in the Commercial
Pharmaceuticals segment, with revenues predominantly from Regional Brands. Aspen
supplies well-established local brands, as well as internationally recognised
medicines across multiple countries in the region, supported by commercial and
sales employees. Extensive and differentiated manufacturing capabilities
including high potency and hormonal solids, vaccines and other state-of-the-art
sterile capabilities exist at one of the Group’s primary manufacturing sites in
Gqeberha, South Africa. This primary site is complemented by five regional sites
across the continent.
Key countries
Egypt
Kenya
Kingdom of Saudi Arabia
South Africa
Tanzania
Number of products launched:
48
(2020: 29)
STATISTICS
The South African private pharmaceutical sector was valued at R49,8 billion MAT*
for the period ended July 2021.
In South Africa, four out of the top 15 brands in the private sector were Aspen
products.
Source: IQVIA, IQVIA Midas 2021 and Market Prognosis Global. South Africa and
Middle East and North Africa only.
Sub-Saharan Africa (“SSA”) not covered by IQVIA
*MAT = Moving annual total
AMERICAS
Aspen’s presence in the Americas is dominated by the businesses in Latin
America. Mexico and Brazil are the largest contributors to regional performance.
Aspen provides a range of trusted brands across prescription, hospital and
over-the-counter medicines and operates one finished dose form manufacturing
facility in Brazil.
Key countries
Brazil
Canada
Chile
Colombia
Ecuador
Mexico
USA
Number of products launched:
3
(2020: 8)
STATISTICS
The Mexican pharmaceutical market grew 14,0% to USD10,8 billion MAT* June 2021,
positively impacted by double-digit growth across the generic and ethical
markets.
Pharmaceutical sales across the total Spanish Latin America market grew 20% to
USD21,3 billion MAT June 2021.
Source: IQVIA – June 2021
*MAT = Moving annual total
ASIA
This region comprises all Asian territories where we sell products, including
China. Active trading subsidiaries include those in China, the Philippines,
Taiwan and Malaysia with other countries in the region reached via distributors.
Sterile Focus Brands are the key contributor to revenue. Our manufacturing
facility in India is our primary new product development site.
Key countries
China
Malaysia
Philippines
Singapore
Taiwan
Number of products launched:
3
(2020: 1)
STATISTICS
The Chinese general anaesthesia therapy area consists of inhalation and
intravenous products. The propofol market grew 10,6% year-on-year MAT* May 2021.
The South Korean pharmaceutical market is forecast to grow at a CAGR of 6%
between 2019 and 2024, reaching Won24,579 billion by 2024.
Source: China IMS CHPA Report, May 2021.
*MAT = Moving annual total
Source: China IMS CHPA Report, May 2021.
*MAT = Moving annual total
AUSTRALASIA
One of the largest pharmaceutical companies in the Australasia region, with a
comprehensive portfolio of medicines comprising Regional Brands, including
prescription and over-the-counter products, as well as Sterile Focus Brands. A
widely-accredited manufacturing facility is operated in Australia, producing
finished dose form solids, liquids and semi-solids as well as packaging for
third party contract manufacturing for domestic and export markets.
Key countries
Australia
New Zealand
Number of products launched:
2
(2020: 2)
STATISTICS
The Australian and New Zealand pharmaceutical market combined, grew 1,9% and was
valued at AUD20,7 billion MAT* to May 2021.
Source: IQVIA – August 2020
*MAT = Moving annual total
EUROPE CIS
Europe CIS provides a broad range of Sterile Focus and Regional Brands while
operating a range of manufacturing facilities for Aspen’s own production needs,
as well as manufacturing for third parties. Sterile Focus Brands comprise
anaesthetics and thrombosis in Russia and the other CIS countries only.
Manufacturing activities include active pharmaceutical ingredients and finished
dose form production and our sites are widely accredited. The prefilled syringe
and multi-dose form sites in France and Germany respectively, provide finished
dose form medicines for commercialisation by Aspen and third parties for both
domestic and export markets.
Key countries
France
Germany
Netherlands
Russian Federation
United Kingdom
Number of products launched:
1
(2020: Nil)
STATISTICS
* © 2022 Aspen Holdings
* Disclaimer
* Privacy Statement
* Aspen PAIA & POPI Manual
* Standard Terms of purchase of goods or services (STC)
* Contact details
* Designed & Produced by Bastion Graphics
* Africa Middle East
* Ghana-Kama
* Kenya-Beta Healthcare
* Mauritius
* MENAT
* Nigeria
* South Africa-Ethicare
* South Africa-FCC
* South Africa-HOLDINGS
* South Africa-Nutritionals
* South Africa-Pharmacare
* Tanzania-Shelys
* Americas
* Brazil
* Canada
* Mexico
* USA
* Asia
* China
* Japan
* Malaysia
* Philippines
* Taiwan
* Australasia
* Australia
* New Zealand
* Europe CIS
* Austria
* Czech Republic
* France
* France-NDB
* Germany
* Netherlands
* Netherlands OSS
* Netherlands-Aspen API
* Russia
* Slovakia
* SPAIN
* SWITZERLAND
* Ghana-Kama
* Kenya-Beta Healthcare
* Mauritius
* MENAT
* Nigeria
* South Africa-Ethicare
* South Africa-FCC
* South Africa-HOLDINGS
* South Africa-Nutritionals
* South Africa-Pharmacare
* Tanzania-Shelys
* Brazil
* Canada
* Mexico
* USA
* China
* Japan
* Malaysia
* Philippines
* Taiwan
* Australia
* New Zealand
* Austria
* Czech Republic
* France
* France-NDB
* Germany
* Netherlands
* Netherlands OSS
* Netherlands-Aspen API
* Russia
* Slovakia
* SPAIN
* SWITZERLAND
You are not a HCP so we cannot give you access to the products
×
Are you health care professional?
Yes No
×
Are you health care professional?
Yes No
×
Are you health care professional?
Yes No
×
Are you health care professional?
Yes No
×
Are you health care professional?
Yes No
×
Are you health care professional?
Yes No
×
Are you health care professional?
Yes No
×
Are you health care professional?
Yes No
×
Scroll To Top